Trial Profile
Phase II Study Of Neoadjuvant Chemotherapy With Gemcitabine, Oxaliplatin And Erlotinib (Gemoxt) In Borderline Resectable Pancreatic Adenocarcinoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Erlotinib; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 01 May 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 24-Feb-2009.
- 24 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.